Industry

SANTA CLARA, Calif.–(BUSINESS WIRE)–ValGenesis Inc., the global leader in digital validation lifecycle management, will showcase its Process Lifecycle Suite, part of the ValGenesis Smart GxP™ platform, at BioProcessing Summit Europe 2026, taking place March 10-12 in Barcelona. The event brings together bioprocessing innovators, scientists, and decision-makers shaping the future of modern biomanufacturing. Many pharmaceutical and … [Read more…]

First and only immunotherapy plus antibody-drug conjugate regimen, used perioperatively, to significantly extend survival for these patients KEYNOTE-B15 is the sixth study demonstrating overall survival with a KEYTRUDA-based regimen in an earlier-stage cancer Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 … [Read more…]

Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million … [Read more…]

Aiming to Develop New Gut Microbiota Test Items and a Personalized Food Recommendation Algorithm TOKYO & YAMAGATA, Japan–(BUSINESS WIRE)–Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa Kirin)—and Metagen, Inc. (Metagen), which promotes end-to-end innovation from gut environment R&D to social implementation, will begin joint research … [Read more…]

Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported … [Read more…]

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as … [Read more…]

More than 9,000 nurses and PSW jobs could be lost by 2027-28 if government does not increase funding TORONTO–(BUSINESS WIRE)–Health care workers represented by the Canadian Union of Public Employees will hold a rally outside local Premier Doug Ford’s office in Etobicoke in response to funding cuts by the provincial government. The government’s fall economic … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Matter Health, a medical group delivering on-site care inside senior-restricted affordable housing communities, today announced the appointment of Sarah Chouinard, MD, as Chief Medical Officer. In this role, Dr. Chouinard will oversee all aspects of clinical delivery and model performance, including quality outcomes, clinical programs, risk management, and overall model performance across Matter … [Read more…]

Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 … [Read more…]